Published on 25 Jan 2022
- Growing existing companies
- Local life
- Health and biotechnologies
The first network of excellence in the microbiome and infectious disease fields, CynbiomeTM, is being created in the Lyon area, launched by Cynbiose, a company specialising in the development and marketing of innovative preclinical models.
Building on its experience in the microbiome and infectious disease fields, Cynbiose is continuing its development in the Lyon area, launching CynbiomeTM alongside 12 partners. This new network of excellence creates a framework for preclinical activities in the Lyon area and strengthens local expertise in infectiology and microbiota. Discover this innovative project, which has capitalised on the quality and diversity of Lyon’s health and life sciences ecosystem.
The innovative CynbiomeTM project
A project that aims to coordinate and dynamise a network of excellence and create a regional preclinical research cluster on experimental microbiomes, Cynbiome is a one-of-a-kind, cutting-edge network that combines:
- a translational model for technological tools,
- scientific and industrial expertise,
- specialised partners for preclinical study of microbiomes.
Funding and support for the CynbiomeTM project from an ecosystem dedicated to infectiology and microbiota
Launching of the network by Cynbiose
In 2020, Cynbiose, a company specialising in the development and marketing of innovative preclinical models, provided €3 million in equity to launch the CynbiomeTM network of excellence.
With additional funding from the French State and the Auvergne-Rhône-Alpes Region, as well as support from Bpifrance, CynbiomeTM received €1.9 million in financing as part of the Investments for the Future Program (PIA).
A host of partners involved in CynbiomeTM
The CynbiomeTM project, accredited by the Lyonbiopôle innovation cluster, has leveraged a dynamic, diverse ecosystem, including:
- Active Biomarkers
- Maat Pharma
Academic research institutes:
- The CarMen laboratory
- The International Centre for Infectiology Research (CIRI)
- The SFR Biosciences research unit
- The Virnext technological research platform
CynbiomeTM: the range of preclinical services
Valued at €278.7 million in 2018, with forecast annual growth of 33% over the 2019-2029 decade, the microbiome market is a strategic development driver for Lyon-area firms.
In order to meet these challenges, CynbiomeTM will thus offer Europe’s only range of preclinical services in this field, targeting the biopharmaceutical industry.
The network aims to develop appropriate preclinical models and analysis tools in the microbiome and infectious disease spheres.
In the future, it will also extend to other fields, including:
- metabolic disorders,
- inflammatory diseases,
- central nervous system diseases.
Cynbiose’s new high-tech building project in the Lyon area
As a company specialising in innovative preclinical models, Cynbiose has chosen to continue developing its activities in the Lyon region.
In 2021, Cynbiose launched the construction of a brand-new high-tech building, scheduled to open in early 2023, primarily dedicated to preclinical research.
The groundbreaking ceremony took place on 18 November 2021, with all the company’s partners, representatives of the Auvergne-Rhône Alpes Region and the French State, and the various stakeholders in this major project in attendance.
This represents a huge step in the development of this French SME, which was founded on the VetAgroSup site in nearby Marcy-l'Étoile (Lyon metropolitan area).
Find out more
Your dedicated specialist
Project Manager, Life Sciences - Health / Lyon-Gerland Biodistrict
Related news •
10 Jul 2023
The Nouveau Centre, an exceptional building in the service of international cancer research, opens in the heart of the Lyon-Gerland Biodistrict
25 May 2023
Ergoflix France, mobility solutions to help people age comfortably and live better, sets up operations in Chassieu
09 Jun 2022
Wood recycling company Valecobois inaugurates its new facility in Givors: here’s a look back at the business setup process with Aderly
09 Mar 2022